Viewing Study NCT02109627

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:06 AM
Ignite Modification Date: 2026-03-09 @ 5:48 AM
Study NCT ID: NCT02109627
Status: TERMINATED
Last Update Posted: 2020-03-24
First Post: 2014-01-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Sponsor: C. Babis Andreadis
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
None Relapsed Acute Myeloid Leukemia View
None Refractory Acute Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myeloid Leukemia View
None Ficlatuzumab View
None High Dose Cytarabine View
None antibody View